



Thymic Tumors: New Developments and Future Directions in Molecularly Informed Therapies

Guest Editors:

Prof. Dr. Philipp Ströbel

Institute of Pathology, University
Medical Center Göttingen,
Göttingen, Germany

Prof. Dr. Alexander Marx

Institute of Pathology, University
Medical Center Göttingen,
Göttingen, Germany

Deadline for manuscript
submissions:

closed (1 December 2023)

Message from the Guest Editors

Thymomas (TM) and thymic carcinomas (TC) are among the adult tumors with the lowest mutational burden, and the oncogenic drivers behind these neoplasms are currently unknown. After more than a decade of molecularly informed therapies, patients with thymomas (TM) and thymic carcinomas (TC) have experienced limited benefits from the latest developments, and the optimal therapy for these tumors remains to be defined. The tumor heterogeneity and profound biological differences between TM and TC necessitate subtype-specific tailored approaches. Due to the rarity of TM and TC, only a few prospective clinical trials have been conducted, often with disappointing results. It is thus of crucial importance that future clinical trials use the best current evidence and all available information.

In this Special Issue, experts in the field will review the status quo of basic research and of the medical treatment of TM and TC, and will suggest directions for future research and informed clinical trials.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)